Carboplatin has major advantages in terms of ease of administration and non-haematological toxicities than cisplatin, although the higher incidence of thrombocytopenia may be a problem in some circumstances. In the main, it can be regarded as an alternative to cisplatin, but current data suggest cisplatin should still be used for treating testicular teratoma. Unlike cisplatin, carboplatin can be used in highdose regimens. Carboplatin should generally be dosed on a pharma-cokinetic basis. In the future, a major role for carboplatin is likely to be in combination with paciltaxel for a variety of tumours.

0 0

Post a comment